Home Blog Page 1155

Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth

CAMBRIDGE, Mass., Dec. 24, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the expansion of its integrated discovery and development framework to support early clinical development and Investigator-Initiated Trials (IITs).  This expansion extends Nona’s capabilities beyond discovery and IND-enabling activities to further strengthen CMC development, toxicology, and GMP manufacturing capabilities. Through strategic partnerships, platform acquisitions, and internal technology innovations, Nona will enable global biopharmaceutical companies to accelerate the clinical trial initiation with rigorous scientific and quality standards.

The expanded framework builds upon Nona’s proprietary platforms, including Harbour Mice®, HBICE®, Hu-mAtrIx™, NonaCarFx™, and Modalities-on-Demand™ and integrates strengthened preclinical and early clinical development capabilities across CMC development, toxicology, and clinical operation. By leveraging extensive partnerships in China and advancing of IITs, Nona enables global biopharmaceutical partners to access established infrastructure and operational efficiency. This approach facilities faster clinical trial initiation while maintaining high standards of global development and regulatory compliance.

“Expanding Nona’s technology platforms and capabilities from antibody discovery to early clinic development represents a natural progression of our strategic vision,” said Dr. Di Hong, Chief Executive Officer of Nona Biosciences. “By combining our proprietary platforms with strategic external collaborations and internal development efforts, we are strengthening our ability to enable efficient clinical translation while remaining focused on building differentiated, scalable technologies.”

With extensive experience spanning more than 300 discovery programs and a growing portfolio of clinically validated platforms, Nona Biosciences continues to advance the future of biologic innovation as a technology-centric company—empowering partners to progress efficiently from discovery through early clinical development using integrated, high-performance platforms.

About Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from discovery to early clinical development and Investigator-Initiated Trials (IITs).

Nona’s proprietary Harbour Mice® technology platform generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. The HCAb Harbour Mice® is the world’s first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications using fully human VH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery platform), Modalities-on-Demand™ (a next-generation modalities solution), and end-to-end preclinical drug development services, Nona Biosciences is dedicated to driving the global invention of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

Global Times: China’s economic potential reflected in auto sector’s ‘three 30-million’ milestones

BEIJING, Dec. 24, 2025 /PRNewswire/ — A video released on Sunday by studio Yishijie offered an explanation of a recent People’s Daily article, stressing that China’s economy is “large not only in scale, but also in potential,” and expressing strong confidence in its long-term development prospects.

The video explains a People’s Daily article originally published on the front page of the newspaper on December 19, 2025, by Ren Ping, which focuses on the widely discussed “three 30-million” milestones in China’s automotive industry.

Xi Jinping, General Secretary of the Communist Party of China (CPC) Central Committee, pointed out that “Our economy is on solid foundations, demonstrating advantages in many areas, strong resilience, and great potential. The conditions and underlying trends supporting long-term growth remain unchanged.”

The Central Economic Work Conference summarized the key principles of conducting economic work under new circumstances with “five imperatives,” with “it is necessary to fully tap economic potential” ranked first.

At the end of October, FAW-Volkswagen rolled out its 30-millionth vehicle. On December 10, Changan Automobile produced its 30-millionth Chinese-brand vehicle. A day later, data released by the China Association of Automobile Manufacturers showed that China’s automobile production and sales both exceeded 31 million units in the first 11 months of this year.

According to the video, these milestones highlight the immense potential of the Chinese market for open, win-win cooperation, the innovation capacity and brand strength of Chinese manufacturing, as well as the advantages of China’s supersized market and its comprehensive industrial system.

The video said that as the world’s second-largest consumer market, China boasts the world’s largest middle-income group and the most comprehensive industrial system, noting that China’s economic potential lies in the transition from old to new drivers, the integration of urban and rural development, and the balanced advancement of people and production.

By tapping momentum from industrial depth, exploring opportunities across geographic space, and fostering new vitality through human development, China’s economy is showing a more pronounced trend toward innovation-driven and high-quality growth, the video said.

The video noted that the auto sector once experienced a period of intensifying “rat-race” competition. In the first quarter of 2025, profit margin of China’s auto industry fell to 3.9 percent, below the average for the manufacturing sector.

However, the video emphasizes that the process of solving problems is also the process of unleashing potential. A series of timely measures has helped steer the industry back on track. The automobile sector reflects broader economic wisdom and plays a key role in releasing economic potential. In this process, the government should act as a guide, a barrier-breaker and a safeguard.

To fully unleash economic potential, the video stresses the importance of applying dialectical thinking and pursuing targeted solutions. Guided by the principle of “coordinating the whole as one chessboard,” it is essential to tailor measures to local conditions to unleash the comparative advantages and developmental potential of each region, pooling them into a powerful driving force for China’s economic development, the video noted.

“The fundamentals of the Chinese economy – its strong resilience, enormous potential, vast room for maneuver and long-term sustainability – remain unchanged,” said Xi, “we have every confidence in the future of China’s economy.”

SI Group Announces Closing of Comprehensive Recapitalization, Positioning the Company for Accelerated Growth

Significant De-leveraging Transaction Resulting in Overall Debt Reduction of Approximately $1.7 Billion

THE WOODLANDS, Texas, Dec. 24, 2025 /PRNewswire/ — SI Group, a leading global developer and manufacturer of performance additives, process solutions and chemical intermediates, today announced the successful completion of a comprehensive recapitalization transaction supported by its lenders and equity partners. Through this transaction, SI Group has reduced its outstanding net indebtedness by approximately $1.7 billion (over 80% reduction) and made amendments to its revolving credit facility, both of which materially enhance SI Group’s financial and operational flexibility going forward. In addition, a new institutional ownership group, has injected $150 million of junior capital, demonstrating their confidence in the company’s long-term outlook. This investment will enable SI Group to fund the company’s working capital needs, invest in key operational initiatives, and accelerate growth to serve the needs of its customers and business partners.

“This recapitalization represents an important step for SI Group,” said David Bradley, President and CEO of SI Group. “By reducing our debt and securing new investment, we have strengthened our financial foundation, allowing us to continue investing in growth, improving operational capabilities, and supporting our customers worldwide. We appreciate the partnership of our new institutional investors, whose commitment reflects confidence in our strategy and positions us for long-term success.”

Advisors
Latham & Watkins LLP served as legal advisor, PJT Partners served as investment banker, AlixPartners LLP served as financial advisor to SI Group. 

Akin Gump Strauss Hauer & Feld LLP served as legal advisor and Lazard served as investment banker to an ad hoc group of the company’s second-out term loan lenders.

Baker Botts L.L.P served as legal advisor to the company’s current equity holders.

About SI Group
SI Group is a global leader in the innovative technology of performance additives, process solutions, and chemical intermediates. SI Group solutions are essential to enhancing the quality and performance of countless industrial and consumer goods within plastics, rubber & adhesives, fuels & lubricants, oilfield, and pharmaceutical industries. SI Group’s global manufacturing footprint includes 18 facilities on three continents, serving customers in 80 countries with approximately 1,600 employees worldwide. In 2025, SI Group received a bronze award for corporate social responsibility by EcoVadis and is ranked among the top 35 percent of the more than 150,000 companies worldwide. SI Group innovates and drives change to create value with a passion for safety, chemistry, sustainability, and extraordinary results. Learn more at www.siigroup.com.

Media Contact:
Joseph Grande
ph: + 1.413.684.2463
joe@jgrandecommunications.com

 

/DISREGARD RELEASE: Shanda Group/

We are advised by Shanda Group that journalists and other readers should disregard the news release, “From Discoverative AI to the Entropy of Tolerance: Tianqiao Chen’s Vision of Human-AI Co-Evolution”, issued on December 23, 2025 by Shanda Group over PR Newswire, as the release plan has changed due to timeline issues.

CodiMe Expands Overseas Business with AI Fashion Image SaaS “Potoo,” Targeting Japan as a Key Market

SEOUL, South Korea, Dec. 24, 2025 /PRNewswire/ — CodiMe Co., Ltd., a fashion AI startup, said it is accelerating its overseas business expansion in 2025, with Japan positioned as a key strategic market for its AI fashion image generation software-as-a-service platform, Potoo.

Potoo is designed to replace traditional model photoshoots in fashion e-commerce by generating high-quality model images using generative AI. With just a single product photo, the platform can produce unlimited model images, significantly reducing production costs and shortening content creation timelines. According to the company, Potoo can cut image production costs by up to 90 percent and reduce lead times from weeks to minutes, while contributing to higher conversion rates on product detail pages and marketing campaigns.

CodiMe reported that Potoo recorded more than sixfold month-on-month revenue growth in 2025, following the rollout of new features that expanded its commercial usability. These include automatic top-and-bottom outfit styling, fixed AI-generated model faces to maintain brand identity, selectable backgrounds, and back-view image generation. The company said the introduction of these features led to an approximately 530 percent increase in monthly revenue within one month of launch.

Japan is emerging as a central focus of CodiMe’s overseas strategy. The company has been actively engaging with Japanese fashion brands, media companies, and e-commerce operators through proof-of-concept projects and partnership discussions. At recent international exhibitions, including VivaTech 2025 in Paris and fashion-related events in Japan, CodiMe said it secured strong interest from Japanese companies, with more than 200 potential clients identified during a three-day exhibition period in Japan alone.

Potoo is powered by CodiMe’s proprietary AI model, trained on more than one million fashion-specific images. This specialized training enables higher realism, accurate color reproduction, and a greater level of automation compared with general-purpose image generation models. In addition, all model faces generated by Potoo are fully AI-created, allowing brands to use the images without concerns related to portrait rights or licensing issues, which is particularly important for global and Japanese enterprises.

CodiMe said Potoo is currently being used by domestic fashion companies in Korea, including major apparel groups, as well as overseas telecom operators, global apparel vendors, and media groups through paid contracts and pilot projects. The company aims to strengthen its presence in Japan by offering localized services and expanding partnerships tailored to the needs of Japanese fashion and retail businesses.

Japan has a sophisticated fashion market with high standards for visual quality and operational efficiency,” Jihye Jung, CEO CodiMe, said. “We see strong potential for AI-generated fashion imagery to support Japanese brands as they seek faster, more flexible content production without compromising brand identity.”

CodiMe’s overseas expansion is supported by its selection for a government-backed export support program operated by South Korea’s Ministry of Science and ICT and the National IT Industry Promotion Agency, which is helping the company scale its global business around Potoo.

Gallery360 to Expand VR Exhibition Platform Globally in 2025, with Japan as a Focus Market

SEOUL, South Korea, Dec. 24, 2025 /PRNewswire/ — Gallery360, a South Korea–based smart art platform company, said it will accelerate the global expansion of its VR exhibition platform in 2025, with Japan positioned as a key market alongside Singapore and Malaysia.

The company operates a VR exhibition service accessed by users in 116 countries and aims to develop the platform into a global online exhibition infrastructure for artists, cultural institutions, and organizations.

Gallery360’s main service, Gallery360 Exhibit, allows users to create VR exhibitions in approximately 10 minutes without specialized technical knowledge. The platform offers more than 50 virtual exhibition spaces, responsive design templates, and built-in functions for invitations, link sharing, and visitor statistics, enabling exhibitions to be viewed online regardless of location.

Each exhibition generates an individual web page and includes features such as digital animations prior to entry, themed virtual spaces, guestbooks, and voting functions. Exhibitions can be shared through unique URLs, with invitations distributed via email or messaging services. The platform provides data on visitor devices, countries, and access times, allowing organizers to analyze exhibition performance.

As of 2025, Gallery360 has supported more than 1,330 exhibition creators, hosted over 2,100 VR exhibitions, and recorded more than 1.7 million visitors, according to the company.

The platform currently supports Korean, English, and Japanese, enabling use across regions and age groups. It has been used for a wide range of content, including fine art, photography, educational programs, and public-sector exhibitions.

Gallery360 has worked with domestic and international partners including UNESCO, Pfizer, World Vision, government agencies, universities, local governments, and cultural institutions. The company holds more than 21 domestic patents related to VR exhibition, artificial intelligence, and artwork management technologies, and has registered trademarks in the United States and China. It has also received multiple industry and government awards and has participated in international technology exhibitions such as MWC Barcelona.

In addition to its software-as-a-service platform, Gallery360 is expanding its business for corporate and institutional clients. These offerings include hybrid online and offline exhibition packages, digital catalogs, group exhibition management tools, and data-based exposure and sponsorship models. The company said these services are being applied not only to art exhibitions but also to education programs, corporate social responsibility activities, and brand-related events.

Japan has a well-established cultural sector and a high level of digital adoption,” said Sally Shin, Chief Executive Officer of Gallery360. “We plan to work with local partners to develop VR exhibition services that complement physical exhibitions and support international cultural exchange.”

Gallery360 said its overseas expansion is supported by its selection for a government-backed export support program operated by South Korea’s Ministry of Science and ICT and the National IT Industry Promotion Agency.

NSF Retail Food Safety Audits Launch in Thailand with Nadimos Lebanese Restaurant as First Site to Achieve Compliance

Verified food retailers and restaurants demonstrate a strong commitment to hygiene, food safety and regulatory compliance

BANGKOK, Dec. 24, 2025 /PRNewswire/ — NSF, a leading global public health and safety organization, today announced that Nadimos Lebanese Restaurant – Silom branch in Bangkok, Thailand, has become the first restaurant in the world to meet the requirements of the NSF Retail Food Safety Essentials audit program. Nadimos may now display the official NSF Food Safety Essentials badge at its location which has met the requirements, demonstrating its dedication to meeting rigorous hygiene and food safety standards.

The NSF Retail Food Safety Audits program is a scalable, independent audit program for the food service, hospitality and retail food sectors. Food Safety Essentials provides a clear, practical framework for small to medium-sized food outlets. Designed to support continuous improvement, the guidelines help businesses meet food safety elements identified by the NSF Food Safety Checklist, intended to help reduce operational risks. Designed using decades of NSF food outlet auditing expertise, the program evaluates four core areas: food safety, cleanliness, repair and maintenance, and brand standards.

The NSF Food Essentials Audit Program is designed to support food safety compliance while delivering the following key benefits:

  • Results that matter: Clients often see a measurable improvement in food safety performance within just a few months of working with NSF.           
  • Data-driven improvements: Audit reports can inform outlets and help them reduce critical food safety issues after consistent auditing and training.   
  • Tailored recommendations: We don’t just point out what’s wrong—we offer clear, actionable steps food outlets can take to address them.
  • Global expertise, local understanding: Our auditors understand local regulations and cultural practices while applying global food safety best practices.
  • Support beyond the audit: We offer training, gap assessments, and follow-up visits to help companies build a long-term food safety culture.

Developed for businesses with single or limited locations, the Food Safety Essentials program helps companies maintain consistent, reliable food safety practices across all sites.

Company locations which meet NSF’s Food Safety Essentials criteria can opt to upgrade their service and receive an official NSF Food Safety Essentials badge for on-site display, along with a detailed audit report outlining findings, improvement opportunities and recommendations.

“We wanted to ensure our restaurant follows the best food safety practices, not just the minimum requirements. Working with NSF helped us to put our customers and employees first by complying with stringent guidelines,” said Mr. Khater El Ghoul, the founder of Nadimos Lebanese Restaurant. “Independent validation from NSF strengthens our commitment to food safety. It gives our team and customers confidence that our practices meet the required standards, building trust and reinforcing our reputation for serving food safely and responsibly.”

Nadimos Lebanese Restaurant offers a fresh approach to Lebanese cuisine in Bangkok, specializing in traditional dishes prepared to the highest standards.

“We are delighted that Nadimos has set a precedent as the first company in the world to undertake this program,” said Sutida Ketudut, director of retail solutions, APAC at NSF. “The NSF Food Safety Essentials program offers clear guidance and practical tools that help food businesses strengthen hygiene practices, enhance compliance and build customer trust. This milestone reflects the growing commitment of Thai businesses to raising food safety standards, and we look forward to supporting many more in the future.”

In addition to Food Safety Essentials, NSF offers Food Safety Plus and Food Safety Advanced as part of its Retail Food Safety Audits Program. This means as organizations grow and evolve, additional audit options are available to support their food safety journey:

NSF Food Safety Plus checks expanding brands and franchise networks are on track to drive consistent food safety across multiple sites, and provides guidance on where to improve.  The program combines tailored audits and digital insights to help companies compare results and monitor progress. Optional customer-facing badges are available for locations which meet the audit requirements.

NSF Food Safety Advanced delivers customized, globally consistent and data-driven food safety audits to help multi-site operators manage risks, ensure compliance and build customer trust.

Learn more about the NSF Retail Food Safety Audits Services Program. 

About NSF

NSF is an independent, global services organization dedicated to improving human health for more than 80 years by developing public health standards and providing world-class testing, inspection, certification, advisory services and digital solutions to the food, water and wellness products industries. NSF has 40,000 clients in 110 countries and is a World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Medical Device Safety.

SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug ‘SNB-101’ on Gastric Cancer.

SEONGNAM, South Korea, Dec. 24, 2025 /PRNewswire/ — SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer.

SNB-101 is the world’s first nanoparticle anticancer drug that has formulated extremely insoluble SN-38 into polymer nanoparticles, which is expected to significantly improve therapeutic efficacy and reduce side effects. It is currently undergoing active clinical development for various solid tumor indications in Korea, Europe, and the U.S.A.

Gastric cancer is classified as an extremely rare disease (with a prevalence <200,000) in the U.S. with a 5-year relative survival rate of only about 36% across all stages. Currently, the standard of care for advanced gastric cancer includes cytotoxic chemotherapy (such as irinotecan and paclitaxel) and targeted therapies like trastuzumab for HER2-positive patients. However, the prognosis for patients with advanced stages remains poor. Many patients eventually develop resistance to these first-line treatments or experience disease progression, leaving them with limited effective therapeutic options. According to SN Bioscience, SNB-101 showed excellent efficacy compared to existing standard of care treatments such as paclitaxel, irinotecan and trastuzumab in gastric cancer animal models.

Orphan drug designation is a program where the US FDA facilitates the development and approval of treatments for rare/incurable or life-threatening diseases. This designation provides the qualified drug developers with various benefits such as exclusive rights for 7 years from the date of marketing approval, tax credits for R&D costs, assistance for clinical trial design for clinical development, exemption from review application fees, and priority review support.

SNB-101 previously received ODDs from the US FDA for small cell lung cancer in July 2023 and pancreatic cancer in February 2024. By receiving an ODD for gastric cancer this time, SN Bioscience expects to gain momentum in indication expansion and clinical development.

About SN BioScience Inc.

SN BioScience is a biotech company established in May 2017. It is a drug delivery system R&D company specialized in anti-cancer drugs and is located in South Korea. SN BioScience was founded by pharmaceutical R&D experts, world-class bio-polymer research professors, and clinical professors. From the beginning of its establishment, it has focused on “commercialization” and has been developing nanoliposomes and nanoparticle drug carriers based on pharmacometrics and pharmacokinetics.

SNB-101

SNB-101 is an anticancer agent that is the world’s first nanoparticle formulation of the anticancer drug SN-38. It uses a delivery system sophisticatedly designed via dual nano-micelle technology which is a core platform technology of SN Bioscience. SN-38 is an active metabolite of irinotecan which is gaining attention for its use in antibody-drug conjugates (ADCs) such as Enhertu® and Trodelvy®. Compared to existing irinotecan products, drug resistance and safety have been significantly improved, and based on the animal studies, it is expected to be effective for lung cancer, pancreatic cancer, and stomach cancer, which were not the indications previously.

SNB-101 successfully completed Phase 1 clinical trials in patients with solid tumors (NCT04640480) and received IND approval for Phase 1b/2 from the US FDA in December 2024 for the treatment of small cell lung cancer. Subsequently, a regulatory protocol review is currently underway in Europe for phase 2 trials, which will evaluate both monotherapy and combination therapy in patients with small cell lung cancer.